MedPath

Amarin Neuroscience Ltd.

🇬🇧United Kingdom
Ownership
Subsidiary
Employees
11
Market Cap
-
Website
http://www.laxdale.co.uk

Clinical Trials

7

Active:6
Completed:1

Trial Phases

1 Phases

Phase 3:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials

Phase 3
1 (100.0%)

TREND-HD - A Trial of Ethyl-EPA (Miraxion™) in Treating Mild to Moderate Huntington's Disease

Phase 3
Completed
Conditions
Huntington Disease
First Posted Date
2005-09-07
Last Posted Date
2007-12-27
Lead Sponsor
Amarin Neuroscience Ltd
Target Recruit Count
300
Registration Number
NCT00146211
Locations
🇺🇸

University of Alabama at Birmingham, Birmingham, Alabama, United States

🇺🇸

Mayo Clinic Arizona, Scottsdale, Arizona, United States

🇺🇸

University of California San Diego, La Jolla, California, United States

and more 37 locations

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.